Last 7 days
-10.1%
Last 30 days
-9.9%
Last 90 days
-18.8%
Trailing 12 Months
-29.9%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-30 | Kulkarni Samarth | acquired | 478,000 | 19.12 | 25,000 | chief executive officer |
2023-05-30 | Kulkarni Samarth | sold | -1,621,890 | 64.8758 | -25,000 | chief executive officer |
2023-05-24 | Morrow Phuong Khanh | sold (taxes) | -166,555 | 65.91 | -2,527 | chief medical officer |
2023-05-23 | Morrow Phuong Khanh | acquired | - | - | 6,938 | chief medical officer |
2023-04-25 | Kulkarni Samarth | acquired | 478,000 | 19.12 | 25,000 | chief executive officer |
2023-04-25 | Kulkarni Samarth | sold | -1,266,640 | 50.6655 | -25,000 | chief executive officer |
2023-03-29 | Kulkarni Samarth | sold | -1,111,500 | 44.4601 | -25,000 | chief executive officer |
2023-03-29 | Kulkarni Samarth | acquired | 478,000 | 19.12 | 25,000 | chief executive officer |
2023-03-13 | Kulkarni Samarth | sold (taxes) | -408,170 | 43.22 | -9,444 | chief executive officer |
2023-03-13 | KASINGER JAMES R. | sold (taxes) | -99,622 | 43.22 | -2,305 | general counsel and secretary |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | 666 | 3,425 | -% |
2023-09-20 | BARCLAYS PLC | added | 3.16 | 4,592,000 | 20,953,000 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -51.29 | -13,215 | 20,210 | -% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | sold off | -100 | -9,363 | - | -% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | 92,724 | 477,134 | 0.03% |
2023-08-25 | Gould Capital, LLC | unchanged | - | 1,200 | 6,175 | -% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 208 | 597,337 | 798,337 | -% |
2023-08-22 | Old North State Trust, LLC | sold off | -100 | -7,000 | - | -% |
2023-08-22 | Asset Dedication, LLC | added | 69.7 | 2,000 | 3,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 59.46 | 327,750 | 662,452 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Apr 11, 2023 | ark investment management llc | 10.16% | 7,990,188 | SC 13G/A | |
Feb 13, 2023 | capital international investors | 7.1% | 5,560,492 | SC 13G | |
Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 5.11% | 4,006,476 | SC 13G/A | |
Feb 14, 2022 | nikko asset management americas, inc. | 5.64% | 4,319,471 | SC 13G/A | |
Feb 11, 2022 | capital international investors | 4.8% | 3,706,004 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 11.88% | 9,087,868 | SC 13G/A | |
Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 5.64% | 4,319,471 | SC 13G/A | |
Sep 10, 2021 | ark investment management llc | 10.03% | 7,644,350 | SC 13G/A | |
Aug 10, 2021 | capital international investors | 5.6% | 4,265,002 | SC 13G/A | |
Feb 16, 2021 | ark investment management llc | 14.62% | 10,412,976 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 07, 2023 | 8-K | Current Report | |
Aug 07, 2023 | S-8 | Employee Benefits Plan | |
Aug 07, 2023 | 8-K | Current Report | |
Aug 07, 2023 | 10-Q | Quarterly Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 143.2B | 26.6B | 4.02% | 19.39% | 17.95 | 5.39 | 0.75% | 21.34% |
GILD | 93.5B | 27.4B | -2.63% | 19.73% | 17.06 | 3.42 | -0.48% | 32.56% |
MRNA | 38.1B | 10.7B | -13.40% | -19.57% | 31.56 | 3.58 | -53.67% | -91.41% |
BIIB | 37.3B | 10.0B | -2.69% | 28.44% | 13.99 | 3.74 | -6.23% | 29.40% |
MID-CAP | ||||||||
NBIX | 11.1B | 1.7B | 5.62% | 10.06% | 62.93 | 6.64 | 29.01% | 1345.90% |
BBIO | 4.4B | - | -4.62% | 161.21% | -7.53 | 48.33 | 54.84% | -12.96% |
DNLI | 3.0B | - | -2.68% | -18.72% | -23.7 | 37.44 | 122.90% | 54.78% |
BEAM | 1.9B | 80.2M | 1.11% | -50.65% | -5.66 | 23.11 | 42.17% | -39.82% |
SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | -14.37% | -21.78% | -5.11 | 12.12 | -70.36% | -531.73% |
REPL | 989.6M | 15.3M | -19.09% | 6.34% | -5.45 | 64.63 | 1090.59% | -36.57% |
NVAX | 672.4M | 1.6B | -20.87% | -68.23% | -1.15 | 0.42 | 23.74% | 60.24% |
FATE | 207.9M | - | -22.14% | -90.61% | -0.98 | 1.52 | 116.83% | 16.61% |
SGMO | 134.5M | - | -14.96% | -84.69% | -0.68 | 0.56 | 113.96% | -15.19% |
VXRT | 108.4M | 2.1M | -15.22% | -67.28% | -1.07 | 52.75 | 487.70% | -8.66% |
IBIO | 3.8M | - | -10.38% | -96.65% | -0.05 | 3.21 | - | -129.46% |
0.5%
-20.0%
100%
93.5%
88.5%
Y-axis is the maximum loss one would have experienced if CRISPR Therapeutics AG was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q2 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 |
Revenue | - | - | - | - | - | - | - | 914,963,000 | 2,258,883,500 | 3,602,804,000 | 577,888,000 | - | - | - | - | - | - | - | - | 40,997,000 | 11,016,000 | 10,178,000 |
Operating Expenses | -2.7% | 643,739,000 | 661,934,000 | 674,359,000 | 701,409,000 | 648,600,000 | 603,265,000 | 541,435,000 | 490,969,000 | 453,843,000 | 293,274,000 | 242,850,000 | 222,160,000 | 199,390,000 | 182,463,000 | 162,067,000 | 148,077,000 | 124,039,000 | 110,553,000 | 105,645,000 | 101,946,000 | - |
S&GA Expenses | -7.5% | 89,562,000 | 96,803,000 | 102,464,000 | 104,973,000 | 101,681,000 | 104,214,000 | 99,690,000 | 100,337,000 | 98,167,000 | 73,694,000 | 63,488,000 | 62,758,000 | 57,414,000 | 54,387,000 | 48,294,000 | 43,075,000 | 41,012,000 | 36,039,000 | 35,845,000 | 36,604,000 | - |
R&D Expenses | -4.9% | 421,667,000 | 443,335,000 | 461,645,000 | 461,185,000 | 428,063,000 | 387,172,000 | 340,567,000 | 273,253,000 | 260,761,000 | 219,580,000 | 179,362,000 | 159,402,000 | 141,976,000 | 128,076,000 | 113,773,000 | 105,002,000 | 83,027,000 | 74,514,000 | 69,800,000 | 65,342,000 | - |
EBITDA | 100.0% | - | -503,452,000 | -626,328,000 | -649,363,000 | -601,681,000 | 337,710,000 | 397,484,000 | 430,027,000 | 462,536,000 | 27,610,000 | 72,031,000 | - | - | - | - | - | - | - | - | - | - |
EBITDA Margin | - | - | - | -522 | -2.83 | -0.66 | 0.37 | 0.43 | 0.51 | 0.59 | 0.05 | 1.76 | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 19.5% | -423,737,000 | -526,636,000 | -650,500,000 | -673,950,000 | -626,574,000 | 316,510,000 | 379,531,000 | 415,846,000 | 451,355,000 | 20,612,000 | 67,306,000 | -10,596,000 | -199,867,000 | -184,537,000 | -164,428,000 | -116,512,000 | -89,938,000 | -73,626,000 | -66,608,000 | -49,670,000 | - |
EBT Margin | - | - | - | -542 | -2.93 | -0.68 | 0.35 | 0.41 | 0.49 | 0.58 | 0.04 | 1.64 | - | - | - | - | - | - | - | - | - | - |
Net Income | 12.2% | -776,312,000 | -884,406,000 | -650,175,000 | -680,848,000 | -633,452,000 | 311,607,000 | 377,661,000 | 411,870,000 | 446,584,000 | 19,578,000 | 66,858,000 | -11,274,000 | -200,408,000 | -185,089,000 | -164,981,000 | -117,251,000 | -91,247,000 | -75,182,000 | -68,357,000 | -51,398,000 | - |
Net Income Margin | - | - | - | -542 | -2.96 | -0.69 | 0.34 | 0.41 | 0.49 | 0.57 | 0.03 | 1.63 | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 100.0% | - | -376,600,000 | -532,929,000 | -508,631,000 | -515,774,000 | 414,365,000 | 457,267,000 | 465,037,000 | 502,192,000 | 45,333,000 | 49,993,000 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -2.1% | 2,197 | 2,244 | 2,243 | 2,353 | 2,463 | 2,606 | 2,752 | 2,822 | 2,900 | 1,958 | 1,828 | 1,485 | 1,047 | 1,007 | 1,067 | 721 | 494 | 498 | 489 | 519 | 353 |
Current Assets | -2.5% | 1,860 | 1,908 | 1,853 | 1,933 | 2,107 | 2,261 | 2,418 | 2,519 | 2,621 | 1,832 | 1,717 | 1,391 | 966 | 929 | 988 | 664 | 438 | 450 | 466 | 497 | 331 |
Cash Equivalents | 29.1% | 445 | 344 | 212 | 494 | 497 | 684 | 923 | 1,012 | 1,647 | 1,126 | 1,169 | 1,041 | 945 | 890 | 944 | 630 | 428 | 438 | 457 | 487 | 320 |
Net PPE | -1.9% | 159 | 162 | 164 | 166 | 165 | 157 | 138 | 106 | 75.00 | 52.00 | 42.00 | 38.00 | 34.00 | 32.00 | 31.00 | 21.00 | 20.00 | 19.00 | 19.00 | 18.00 | 18.00 |
Liabilities | -2.2% | 381 | 389 | 368 | 399 | 373 | 361 | 352 | 309 | 296 | 152 | 164 | 142 | 136 | 121 | 127 | 129 | 127 | 118 | 97.00 | 102 | 88.00 |
Current Liabilities | -9.5% | 133 | 147 | 121 | 151 | 120 | 114 | 120 | 96.00 | 100 | 83.00 | 94.00 | 84.00 | 75.00 | 55.00 | 57.00 | 80.00 | 31.00 | 28.00 | 28.00 | 32.00 | 18.00 |
Shareholder's Equity | -2.1% | 1,816 | 1,855 | 1,875 | 1,954 | 2,091 | 2,245 | 2,399 | 2,513 | 2,604 | 1,805 | 1,664 | 1,343 | 911 | 886 | 939 | 592 | 368 | 380 | 392 | 417 | 265 |
Retained Earnings | -8.6% | -976 | -899 | -846 | -735 | -560 | -375 | -195 | -54.67 | 72.00 | -686 | -573 | -466 | -374 | -294 | -224 | -255 | -393 | -339 | -291 | -243 | -193 |
Additional Paid-In Capital | 1.4% | 2,799 | 2,761 | 2,735 | 2,709 | 2,670 | 2,635 | 2,598 | 2,566 | 2,530 | 2,490 | 2,236 | 1,808 | 1,283 | 1,179 | 1,162 | 846 | 760 | 718 | 682 | 660 | 457 |
Shares Outstanding | 0.6% | 79.00 | 79.00 | 79.00 | 78.00 | 78.00 | 77.00 | 77.00 | 76.00 | 76.00 | 75.00 | 74.00 | 70.00 | 61.00 | 61.00 | 61.00 | 55.00 | 53.00 | 52.00 | 52.00 | 47.00 | 47.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 2.5% | -342 | -351 | -495 | -221 | -444 | 504 | 539 | 544 | 549 | -286 | -238 | -153 | 55.00 | 48.00 | 57.00 | 25.00 | -128 | -117 | -96.24 | -82.71 | -78.61 |
Share Based Compensation | -3.3% | 90.00 | 93.00 | 98.00 | 52.00 | 103 | 106 | 102 | 96.00 | 87.00 | 74.00 | 66.00 | 59.00 | 53.00 | 49.00 | 44.00 | 45.00 | 42.00 | 39.00 | 35.00 | 29.00 | 26.00 |
Cashflow From Investing | 1037.6% | 247 | -26.31 | -258 | -123 | -744 | -982 | -1,035 | -1,230 | -996 | -706 | -541 | -329 | -2.00 | -0.57 | 1.00 | -6.73 | -4.97 | -3.31 | -2.77 | -1.98 | -4.78 |
Cashflow From Financing | 19.2% | 40.00 | 33.00 | 39.00 | 17.00 | 38.00 | 36.00 | 251 | 657 | 1,160 | 1,241 | 1,016 | 908 | 466 | 406 | 431 | 125 | 242 | 216 | 316 | 318 | 131 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenue: | ||||
Total revenue | $ 70,000 | $ 158 | $ 170,000 | $ 1,098 |
Operating expenses: | ||||
Research and development | 101,555 | 123,223 | 201,490 | 241,468 |
General and administrative | 19,032 | 26,273 | 41,392 | 54,294 |
Collaboration expense, net | 44,636 | 33,922 | 86,828 | 64,568 |
Total operating expenses | 165,223 | 183,418 | 329,710 | 360,330 |
Loss from operations | (95,223) | (183,260) | (159,710) | (359,232) |
Other income: | ||||
Other income, net | 18,406 | 3,544 | 31,148 | 3,907 |
Total other income, net | 18,406 | 3,544 | 31,148 | 3,907 |
Net loss before income taxes | (76,817) | (179,716) | (128,562) | (355,325) |
Provision for income taxes | (923) | (6,118) | (2,243) | (9,726) |
Net loss | (77,740) | (185,834) | (130,805) | (365,051) |
Foreign currency translation adjustment | 28 | (69) | 60 | (95) |
Unrealized gain (loss) on marketable securities | 452 | (3,380) | 6,679 | (15,180) |
Comprehensive loss | $ (77,260) | $ (189,283) | $ (124,066) | $ (380,326) |
Net loss per common share - basic | $ (0.98) | $ (2.4) | $ (1.66) | $ (4.72) |
Basic weighted-average common shares outstanding | 79,091,061 | 77,513,327 | 78,885,168 | 77,306,970 |
Net loss per common share - diluted | $ (0.98) | $ (2.4) | $ (1.66) | $ (4.72) |
Diluted weighted-average common shares outstanding | 79,091,061 | 77,513,327 | 78,885,168 | 77,306,970 |
Collaboration Revenue [Member] | ||||
Revenue: | ||||
Total revenue | $ 70,000 | $ 158 | $ 170,000 | $ 336 |
Grant Revenue [Member] | ||||
Revenue: | ||||
Total revenue | $ 0 | $ 0 | $ 0 | $ 762 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 444,796 | $ 211,885 |
Marketable securities | 1,323,307 | 1,603,433 |
Accounts receivable | 70,000 | 0 |
Prepaid expenses and other current assets | 21,469 | 37,708 |
Total current assets | 1,859,572 | 1,853,026 |
Property and equipment, net | 159,172 | 163,634 |
Marketable securities, non-current | 4,901 | 53,130 |
Intangible assets, net | 43 | 71 |
Restricted cash | 11,799 | 11,635 |
Operating lease assets | 159,352 | 156,921 |
Other non-current assets | 2,175 | 4,640 |
Total assets | 2,197,014 | 2,243,057 |
Current liabilities: | ||
Accounts payable | 27,588 | 27,428 |
Accrued expenses | 89,838 | 77,682 |
Accrued tax liabilities | 558 | 135 |
Operating lease liabilities | 14,833 | 15,842 |
Other current liabilities | 20 | 20 |
Total current liabilities | 132,837 | 121,107 |
Deferred revenue, non-current | 12,323 | 12,323 |
Operating lease liabilities, net of current portion | 230,342 | 228,179 |
Other non-current liabilities | 5,484 | 5,969 |
Total liabilities | 380,986 | 367,578 |
Commitments and contingencies, see Note 7 | ||
Shareholders’ equity: | ||
Common shares, CHF 0.03 par value, 79,552,682 and 78,692,766 shares issued at June 30, 2023 and December 31, 2022, respectively, 79,372,366 and 78,512,450 shares outstanding at June 30, 2023 and December 31, 2022, respectively | 2,474 | 2,441 |
Treasury shares, at cost, 180,316 shares at June 30, 2023 and at December 31, 2022 | (63) | (63) |
Additional paid-in capital | 2,799,420 | 2,734,838 |
Accumulated deficit | (976,895) | (846,090) |
Accumulated other comprehensive loss | (8,908) | (15,647) |
Total shareholders' equity | 1,816,028 | 1,875,479 |
Total liabilities and shareholders’ equity | $ 2,197,014 | $ 2,243,057 |